This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [01.11.2019] – [with additional studies] sallieq | home:food:aim_health:aging [02.01.2019] – [Long term treatment] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== | + | ====== |
Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
Line 17: | Line 17: | ||
The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
+ | |||
+ | Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
+ | |||
+ | ==== General research on aging ==== | ||
+ | |||
+ | When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. | ||
+ | |||
+ | These articles have identified holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin D, daily or as a bolus, does not reduce the risk of cardiovascular events. (({{pubmed> | ||
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| | ||
Line 102: | Line 110: | ||
=== Long term treatment === | === Long term treatment === | ||
- | Data suggest 40 & 80 mg olmesartan | + | |
// | // | ||
{{tag> | {{tag> | ||